Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus LOCORTEN.
CAPEX vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid